Free Trial

LivaNova (LIVN) Stock Forecast & Price Target

LivaNova logo
$47.59 +0.10 (+0.21%)
(As of 12/20/2024 05:40 PM ET)

LivaNova - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
6

Based on 7 Wall Street analysts who have issued ratings for LivaNova in the last 12 months, the stock has a consensus rating of "Buy." Out of the 7 analysts, 1 has given a hold rating, 5 have given a buy rating, and 1 has given a strong buy rating for LIVN.

Consensus Price Target

$69.17
45.34% Upside
According to the 7 analysts' twelve-month price targets for LivaNova, the average price target is $69.17. The highest price target for LIVN is $75.00, while the lowest price target for LIVN is $61.00. The average price target represents a forecasted upside of 45.34% from the current price of $47.59.
Get the Latest News and Ratings for LIVN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for LivaNova and its competitors.

Sign Up

LIVN Analyst Ratings Over Time

TypeCurrent Forecast
12/22/23 to 12/21/24
1 Month Ago
11/22/23 to 11/21/24
3 Months Ago
9/23/23 to 9/22/24
1 Year Ago
12/22/22 to 12/22/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
4 Buy rating(s)
1 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
4 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$69.17$69.17$70.80$58.60
Forecasted Upside45.34% Upside33.78% Upside39.51% Upside13.17% Upside
Consensus Rating
Buy
Buy
Buy
Hold

LIVN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

LIVN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

LivaNova Stock vs. The Competition

TypeLivaNovaMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.81
2.51
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside45.34% Upside25,828.65% Upside14.54% Upside
News Sentiment Rating
Positive News

See Recent LIVN News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/25/2024Needham & Company LLC
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$75.00 ➝ $75.00+46.14%
10/31/2024Mizuho
2 of 5 stars
 Lower TargetOutperform ➝ Outperform$80.00 ➝ $70.00+38.04%
10/31/2024Robert W. Baird
2 of 5 stars
 Boost TargetOutperform ➝ Outperform$66.00 ➝ $72.00+40.24%
10/4/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Roman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$65.00+22.16%
9/17/2024Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Rescott
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
7/25/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$70.00 ➝ $72.00+33.80%
2/26/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$57.00 ➝ $61.00+6.79%
9/6/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$52.00-4.43%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 11:37 AM ET.


LIVN Forecast - Frequently Asked Questions

According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for LivaNova is $69.17, with a high forecast of $75.00 and a low forecast of $61.00.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LivaNova in the last twelve months. There is currently 1 hold rating, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" LIVN shares.

According to analysts, LivaNova's stock has a predicted upside of 45.34% based on their 12-month stock forecasts.

LivaNova has been rated by research analysts at Mizuho, Needham & Company LLC, Robert W. Baird, and The Goldman Sachs Group in the past 90 days.

Analysts like LivaNova more than other "medical" companies. The consensus rating for LivaNova is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how LIVN compares to other companies.


This page (NASDAQ:LIVN) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners